Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.
FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.
Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.
FDA's Patrizia Cavazzoni to retire as CDER chief in 2nd senior official's departure in span of weeks
The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...
The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...
According to CDER Director Patrizia Cavazzoni, CDER’s new Center for Real-World Evidence Innovation represents a major step ...
It’s the second time in less than a month that retailer has recalled the medication; this time due to a potential foreign ...
“Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process,” said Patrizia Cavazzoni, M.D., director of the ...
The FDA recommended patients obtain drugs with "a prescription from their doctor and fill the prescription at a state-licensed pharmacy." Patrizia Cavazzoni, the director of the FDA’s Center for ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...
The FDA recommended patients obtain drugs with "a prescription from their doctor and fill the prescription at a state-licensed pharmacy." Patrizia Cavazzoni, the director of the FDA’s Center for Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback